Detailed Information on Publication Record
2021
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. P. LUTZ et. al.Basic information
Original name
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
Authors
KOESSLER, T. (guarantor), M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. P. LUTZ, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA and M. MOEHLER
Edition
British journal of cancer, London, Nature Publishing Group, 2021, 0007-0920
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 9.075
RIV identification code
RIV/00216224:14110/21:00124160
Organization unit
Faculty of Medicine
UT WoS
000687550400002
Keywords in English
Gastrointestinal tract cancer; ASCO-GI 2021
Tags
International impact, Reviewed
Změněno: 15/2/2022 12:33, Mgr. Tereza Miškechová
Abstract
V originále
Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.